We therefore evaluated the therapeutic potential of the Ca2+ activator curcumin combined with the FBXL2 activator nebivolol in the treatment of the third-generation TKI osimertinib-resistant NSCLC. This evidence concerns the gene FBXL2 and non-small cell lung carcinoma.